Cite

HARVARD Citation

    Deng, H. et al. (2020). Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer. Medicine. 99 (25), p. . [Online]. 
  
Back to record